|
1
|
Ahmed S, Kamel MS, Aboelez MO, Ma X, Al-Karmalawy AA, Mousa SAS, Shokr EK, Abdel-Ghany H, Belal A, El Hamd MA, Al Shehri ZS, El Aleem Ali Ali El-Remaily MA. Thieno[2,3- b]thiophene Derivatives as Potential EGFR WT and EGFRT 790M Inhibitors with Antioxidant Activities: Microwave-Assisted Synthesis and Quantitative In Vitro and In Silico Studies. ACS Omega 2022; 7:45535-45544. [PMID: 36530244 PMCID: PMC9753534 DOI: 10.1021/acsomega.2c06219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 11/08/2022] [Indexed: 05/13/2023]
Abstract
Microwave-assisted synthesis and spectral analysis of certain novel derivatives of 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbonitrile 1-7 were carried out. Compounds 1-7 were examined for cytotoxicity against MCF-7 and A549 cell lines using the quantitative MTT method, and gefitinib and erlotinib were used as reference standards. Compounds 1-7 were shown to be more active than erlotinib against the two cell lines tested. Compound 2 outperformed regular erlotinib by 4.42- and 4.12-fold in MCF-7 and A549 cells, respectively. The most cytotoxic compounds were subsequently studied for their suppression of kinase activity using the homogeneous time-resolved fluorescence assay versus epidermal growth factor receptor (EGFRWT) and EGFR790M. With IC50 values of 0.28 ± 0.03 and 5.02 ± 0.19, compound 2 was demonstrated to be the most effective against both forms of EGFR. Furthermore, compound 2 also had the best antioxidant property, decreasing the radical scavenging activity by 78%. Molecular docking research, on the other hand, was carried out for the analyzed candidates (1-7) to study their mechanism of action as EGFR inhibitors. In silico absorption, distribution, metabolism, excretion, and toxicity tests were also performed to explain the physicochemical features of the examined derivatives.
Collapse
Affiliation(s)
- Sanaa
A. Ahmed
- Department
of Pharmacology, Faculty of Medicine, Sohag
University, Sohag82524, Egypt
| | - Moumen S. Kamel
- Department
of Chemistry, Faculty of Science, Sohag
University, Sohag82524, Egypt
| | - Moustafa O. Aboelez
- Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag82524, Egypt
| | - Xiang Ma
- School
of Pharmacy, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan430030, China
| | - Ahmed A. Al-Karmalawy
- Pharmaceutical
Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th
of October City, Giza12566, Egypt
| | - Sayed A. S. Mousa
- Department
of Chemistry, Faculty of Science, Al-Azhar
University, Assiut Branch, Assiut71524, Egypt
| | - Elders Kh. Shokr
- Department
of Physics, Faculty of Science, Sohag University, Sohag82524, Egypt
| | - H. Abdel-Ghany
- Department
of Chemistry, Faculty of Science, Sohag
University, Sohag82524, Egypt
| | - Amany Belal
- Department
of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef62514, Egypt
- Department
of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif21944, Saudi Arabia
| | - Mohamed A. El Hamd
- Department
of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra11961, Saudi Arabia
- Department of Pharmaceutical Analytical Chemistry, Faculty
of Pharmacy, South Valley University, Qena83523, Egypt
- . Phone: +966554117991
| | - Zafer S. Al Shehri
- Department of Medical Laboratories, College
of Applied Medical Sciences, Shaqra University, Shaqra11961, Saudi Arabia
| | | |
Collapse
|
|
3
|
Alanazi IO, Al Shehri ZS, Ebrahimie E, Giahi H, Mohammadi-Dehcheshmeh M. Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other. Mol Carcinog 2019; 58:862-874. [PMID: 30644608 DOI: 10.1002/mc.22975] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 01/07/2019] [Accepted: 01/08/2019] [Indexed: 12/11/2022]
Abstract
A considerable number of deposited variants has provided new possibilities for knowledge discovery in different types of prostate cancer. Here, we analyzed variants located on 3'UTR, 5'UTR, CDs, Intergenic, and Intronic regions in castration-resistant prostate cancer (8496 variants), familial prostate cancer (3241 variants), metastatic castration-resistant prostate cancer (3693 variants), and prostate cancer (16599 variants). Chromosome regions 10p15-p14 and 2p13 were highly enriched (P < 0.00001) for variants located in 3'UTR, 5'UTR, CDs, intergenic, and intronic regions in castration-resistant prostate cancer. In contrast, 10p15-p14, 10q23.3, 12q13.11, 13q12.3, 1q25, and 8p22 regions were enriched (P < 0.001) in familial prostate cancer. In metastatic castration-resistant prostate cancer, 10p15-p14, 10q23.3, 11q22-q23, 14q21.1, and 14q32.13 were highly variant regions (P < 0.001). Chromosome 2 and chromosome 1 hosted many enriched variant regions. AKR1C3, BRCA1, BRCA2, CHGA, CYP19A1, HOXB13, KLK3, and PTEN contained the highest number of 3'UTR, 5'UTR, CDs, Intergenic, and Intronic variants. Network analysis showed that these genes are upstream of important functions including prostate gland development, tumor recurrence, prostate cancer-specific survival, tumor progression, cancer mortality, long-term survival, cancer recurrence, angiogenesis, and AR. Interestingly, all of EGFR, JAK2, NR3C1, PDZD2, and SEMA3C genes had single nucleotide polymorphisms (SNP) in castration-resistant prostate cancer, consistent with high selection pressure on these genes during drug treatment and consequent resistance. High occurrence of variants in 3'UTRs suggests the importance of regulatory variants in different types of prostate cancer; an area that has been neglected compared with coding variants. This study provides a comprehensive overview of genomic regions contributing to different types of prostate cancer.
Collapse
Affiliation(s)
- Ibrahim O Alanazi
- National Center for Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
| | - Zafer S Al Shehri
- Clinical Laboratory Department, College of Applied Medical Sciences, Shaqra University, KSA, Al dawadmi, Saudi Arabia
| | - Esmaeil Ebrahimie
- Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.,School of Information Technology and Mathematical Sciences, Division of Information Technology, Engineering and the Environment, The University of South Australia, Adelaide, SA, Australia.,Institute of Biotechnology, Shiraz University, Shiraz, Iran.,Faculty of Science and Engineering, School of Biological Sciences, Flinders University, Adelaide, SA, Australia
| | - Hassan Giahi
- Institute of Biotechnology, Shiraz University, Shiraz, Iran
| | - Manijeh Mohammadi-Dehcheshmeh
- Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, South Australia, Australia
| |
Collapse
|